Molecular Partners
Develops designed ankyrin repeat protein platform therapies used in ophthalmology, oncology, inflammation, and other therapeutic treatments. Learn more
Launch date
Employees
Market cap
CAD243m
Enterprise valuation
(CAD6m) (Public information from Sep 2024)
Share price
$4.67 MOLN
Company register number CH-020.3.028.228-2
Zurich Canton of Zürich (HQ)
Authorizing premium user...